about
Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.Alterations in the E3 ligases Parkin and CHIP result in unique metabolic signaling defects and mitochondrial quality control issues.Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.A PGAM5-KEAP1-Nrf2 complex is required for stress-induced mitochondrial retrograde trafficking.Bilirubin neurotoxicity is associated with proteasome inhibition.The Proteasome in Modern Drug Discovery: Second Life of a Highly Valuable Drug TargetInhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity.Therapeutic Strategies against Epstein-Barr Virus-Associated Cancers Using Proteasome Inhibitors.Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.Integration of multiple networks and pathways identifies cancer driver genes in pan-cancer analysis.In vitro efficacy of a first-generation valosin-containing protein inhibitor (CB-5083) against canine lymphoma.A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.Positioning of proteasome inhibitors in therapy of solid malignancies.A dystroglycan mutation (p.Cys667Phe) associated to muscle-eye-brain disease with multicystic leucodystrophy results in ER-retention of the mutant protein.Probing the cooperativity of Thermoplasma acidophilum proteasome core particle gating by NMR spectroscopy.The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.Blocking protein quality control to counter hereditary cancers.Potent Inhibitors of Mycobacterium tuberculosis Growth Identified by Using in-Cell NMR-based Screening.Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma.Identification of genomic expression differences between right-sided and left-sided colon cancer based on bioinformatics analysis.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphatDelineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis.Proteasome inhibition blocks necroptosis by attenuating death complex aggregation.Unlocking the NF-κB Conundrum: Embracing Complexity to Achieve Specificity.2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy.PSMD5 inactivation promotes 26S proteasome assembly during colorectal tumor progression.Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation.Ubiquitin-Dependent Regulation of the Mammalian Hippo Pathway: Therapeutic Implications for Cancer.Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.Oncogenic addiction to high 26S proteasome level.Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ InhibitorsProteomic approach for understanding milder neurotoxicity of Carfilzomib against BortezomibReporter PET Images Bortezomib Treatment-Mediated Suppression of Cancer Cell Proteasome Activity
P2860
Q33873351-47C9F14D-3B32-4230-B297-1F2258253212Q38603276-3D0BFA33-2760-4BB7-9975-DB29DF8EE30BQ38605030-4DD54AED-22D0-46F0-B73F-B6798A3CA604Q38609453-30B34F07-2A71-479C-8385-813A48F8DEE7Q41084319-674B9A87-99F8-430C-874D-A2F2BE6990EDQ41519882-4FCE3065-BD06-4E77-9A9B-5DBED2F678ADQ45074664-1DE81073-C52B-4C0F-A6A6-DA8D45CFB048Q45324502-DA08E15F-7076-4B58-998E-6B5C87DE09F5Q47102326-732032E3-AB1D-4C01-B4AB-4F4055F3882FQ47204660-28E24A26-A498-4863-A5CE-C5A8D66E02B0Q47219014-9267DB8A-AB59-4BFC-8D05-84EAD666DBCEQ47292306-7AF0CF56-BA44-4CE2-B3A8-1EBC3FBF1045Q47353792-113E2691-87CD-41EA-9DD9-F0EA6E2A70DFQ47405948-9093B086-B618-4A15-9EC1-7BB7571DB41BQ47583613-4A255FB9-E48C-48C2-A010-D13F332E4321Q47611637-C466C6E6-B41F-4CF1-8464-839897A99AF0Q47988257-98BFE017-B229-405D-B5EE-46985D13799BQ48186323-78938901-B865-4187-966F-9A657671311BQ49166966-782848F0-C5E6-4706-B556-8043A51040B3Q49885724-1DB9472C-9924-47DF-A4CF-9786A2A1ABD6Q50086043-BCA9F2EB-8C87-4278-890A-F9D72B901DFAQ50316561-DAFEF25A-85A3-453F-82AA-F14B03079951Q52370139-24496628-AB49-4560-A38E-97A23207FC2CQ52538370-2F3F6D81-A496-4998-8E07-B40C6EA7A3F8Q52676389-67913A22-71CD-4CEA-B7E9-2D87B4F56480Q52714964-DF8057C7-898C-4415-9B6D-4C97F390E7C2Q52716160-98C49662-0067-4F5C-8054-1999019DC7E6Q54973587-209D2B07-AD61-4B96-BDB7-F2668E08C438Q55027177-EAE89B8A-8B61-49B9-B04A-99E1D00E6375Q55559653-95FB5C65-44F2-4F42-9CE4-1E816E7FD08CQ57167736-E236A198-B90D-449F-A0C6-9DE8B5C3DC67Q58612405-BE3A098A-3F2C-4CC0-8DE4-9926BE540385Q58774592-9AB811D7-7203-4151-8AAE-7888AC7C93F5
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Proteasome inhibitors in cancer therapy.
@en
Proteasome inhibitors in cancer therapy.
@nl
type
label
Proteasome inhibitors in cancer therapy.
@en
Proteasome inhibitors in cancer therapy.
@nl
prefLabel
Proteasome inhibitors in cancer therapy.
@en
Proteasome inhibitors in cancer therapy.
@nl
P2860
P1476
Proteasome inhibitors in cancer therapy.
@en
P2093
Elisabet E Manasanch
P2860
P304
P356
10.1038/NRCLINONC.2016.206
P407
P577
2017-01-24T00:00:00Z